Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
5
×
clinical trials
roche
san francisco blog main
avapritinib
blueprint medicines
deals
eli lilly
fda
genentech
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
san francisco top stories
selpercatinib
thyroid cancer
alexion pharmaceuticals
ally bridge group
alnylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
boehringer ingelheim
cancer
cancer drugs
capmatinib
casdin capital
cstone pharmaceuticals
diabetic nephropathy
dicerna pharamceuticals
What
drug
5
×
medicines
5
×
genetic
approval
blueprint
cancer
diseases
fda
ipo
muscle
ret
roche
team
address
ago
analysis
approves
bio
biotech
biotechs
bring
candidate
carries
caught
causing
certain
company
considering
currently
data
designed
develop
dicerna
disease
dyne
early
employing
expected
experimental
eye
Language
unset
Current search:
medicines
×
drug
×
boston
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug